Snake venom hydrogel to stop bleeding quickly

A nanofibre hydrogel infused with snake venom can stop bleeding within seconds, scientists, including one of Indian-origin, have found.
The hydrogel called SB50 incorporates batroxobin, a venom produced by two species of South American pit viper.
It can be injected as a liquid and quickly turns into a gel that conforms to the site of a wound, keeping it closed, and promotes clotting within seconds, researchers said.
Rice University chemist Jeffrey Hartgerink, lead author Vivek Kumar and their colleagues said the hydrogel may be most useful for surgeries, particularly for patients who take anti-coagulant drugs to thin their blood.
Batroxobin was recognised for its properties as a coagulant - a substance that encourages blood to clot - in 1936. It has been used in various therapies as a way to remove excess fibrin proteins from the blood to treat thrombosis and as a topical hemostat.

It has also been used as a diagnostic tool to determine blood-clotting time in the presence of heparin, an anti-coagulant drug.

"There's a lot of different things that can trigger blood coagulation, but when you're on heparin, most of them don't work, or they work slowly or poorly. That obviously causes problems if you're bleeding," Hartgerink said.
"Heparin blocks the function of thrombin, an enzyme that begins a cascade of reactions that lead to the clotting of blood," he said.
"Batroxobin is also an enzyme with similar function to thrombin, but its function is not blocked by heparin. This is important because surgical bleeding in patients taking heparin can be a serious problem.

"The use of batroxobin allows us to get around this problem because it can immediately start the clotting process, regardless of whether heparin is there or not," he added.
The batroxobin used in this research was not taken directly from snakes. The substance used for medicine was produced by genetically modified bacteria and then purified, avoiding the risk of other contaminant toxins.
The Rice researchers combined batroxobin with their synthetic, self-assembling nanofibres, which can be loaded into a syringe and injected at the site of a wound, where they reassemble themselves into a gel.
Tests showed the new material stopped a wound from bleeding in as little as six seconds, and further prodding of the wound minutes later did not reopen it.

The researchers also tested several other options: the hydrogel without batroxobin, the batroxobin without the hydrogel, a current clinical hemostat known as GelFoam and an alternative self-assembling hemostat known as Puramatrix and found that none were as effective, especially in the presence of anti-coagulants.
"We think SB50 has great potential to stop surgical bleeding, particularly in difficult cases in which the patient is taking heparin or other anti-coagulants," Hartgerink said.